Werewolf Therapeutics (HOWL) Competitors $1.54 -0.03 (-1.91%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOWL vs. AVIR, FDMT, CMRX, ACIU, ITOS, LFCR, FULC, RZLT, BNTC, and LRMRShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Atea Pharmaceuticals (AVIR), 4D Molecular Therapeutics (FDMT), Chimerix (CMRX), AC Immune (ACIU), iTeos Therapeutics (ITOS), Lifecore Biomedical (LFCR), Fulcrum Therapeutics (FULC), Rezolute (RZLT), Benitec Biopharma (BNTC), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Atea Pharmaceuticals 4D Molecular Therapeutics Chimerix AC Immune iTeos Therapeutics Lifecore Biomedical Fulcrum Therapeutics Rezolute Benitec Biopharma Larimar Therapeutics Atea Pharmaceuticals (NASDAQ:AVIR) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation. Does the MarketBeat Community prefer AVIR or HOWL? Werewolf Therapeutics received 13 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 68.89% of users gave Werewolf Therapeutics an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Werewolf TherapeuticsOutperform Votes3168.89% Underperform Votes1431.11% Do analysts prefer AVIR or HOWL? Atea Pharmaceuticals presently has a consensus price target of $6.88, indicating a potential upside of 111.69%. Werewolf Therapeutics has a consensus price target of $12.00, indicating a potential upside of 679.22%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to AVIR or HOWL? In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for Atea Pharmaceuticals and 0 mentions for Werewolf Therapeutics. Atea Pharmaceuticals' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score. Company Overall Sentiment Atea Pharmaceuticals Neutral Werewolf Therapeutics Neutral Do institutionals & insiders hold more shares of AVIR or HOWL? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 17.8% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, AVIR or HOWL? Atea Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Which has better earnings & valuation, AVIR or HOWL? Werewolf Therapeutics has lower revenue, but higher earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea Pharmaceuticals$351.37M0.78-$135.96M-$2.07-1.57Werewolf Therapeutics$3.39M20.27-$37.37M-$1.53-1.01 Is AVIR or HOWL more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Atea Pharmaceuticals' return on equity of -34.90% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Werewolf Therapeutics -578.80%-58.83%-38.45% SummaryWerewolf Therapeutics beats Atea Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.63M$6.70B$5.23B$9.28BDividend YieldN/A2.99%5.12%4.28%P/E Ratio-1.0110.5587.6917.28Price / Sales20.27199.271,168.48119.95Price / CashN/A57.1543.2337.83Price / Book0.505.174.834.94Net Income-$37.37M$151.96M$120.76M$225.76M7 Day Performance-1.91%3.11%2.49%3.92%1 Month Performance-21.43%-4.17%17.55%1.71%1 Year Performance-56.37%7.50%28.51%15.79% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.2083 of 5 stars$1.54-1.9%$12.00+679.2%-52.2%$68.63M$3.39M-1.0140AVIRAtea Pharmaceuticals2.5185 of 5 stars$3.27+2.5%$6.88+110.4%+3.2%$276.19M$351.37M-1.5870FDMT4D Molecular Therapeutics2.4741 of 5 stars$5.92-6.2%$42.56+618.8%-71.9%$273.67M$17,000.00-2.08201CMRXChimerix4.1122 of 5 stars$3.01+0.7%$8.50+182.4%+258.7%$270.71M$159,000.00-3.2072ACIUAC Immune2.4756 of 5 stars$2.73+1.9%$12.00+339.6%-38.1%$270.11M$40.97M-5.93140Positive NewsITOSiTeos Therapeutics3.5568 of 5 stars$7.25-2.3%$22.25+206.9%-31.5%$264.87M$35M-2.3090LFCRLifecore Biomedical2.9822 of 5 stars$7.04-2.8%$10.00+42.0%+20.3%$259.26M$128.44M88.00690FULCFulcrum Therapeutics1.6627 of 5 stars$4.74+9.0%$9.33+96.9%-27.5%$255.67M$80.87M-15.29100Positive NewsHigh Trading VolumeRZLTRezolute3.2129 of 5 stars$4.41+0.5%$24.13+447.1%+390.0%$255.53MN/A-3.4740Positive NewsBNTCBenitec Biopharma3.6765 of 5 stars$11.00-3.6%$24.43+122.1%+247.7%$255.38M$80,000.00-3.8720High Trading VolumeLRMRLarimar Therapeutics1.548 of 5 stars$4.00-0.2%$20.43+410.7%-11.7%$255.23MN/A-3.4830 Related Companies and Tools Related Companies Atea Pharmaceuticals Alternatives 4D Molecular Therapeutics Alternatives Chimerix Alternatives AC Immune Alternatives iTeos Therapeutics Alternatives Lifecore Biomedical Alternatives Fulcrum Therapeutics Alternatives Rezolute Alternatives Benitec Biopharma Alternatives Larimar Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOWL) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
